NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Regentis Biomaterials' New U.S. Patent for GelrinC Liquid Formulation
TL;DR
Regentis Biomaterials secures a patent through 2038 for its GelrinC liquid formulation, giving it a competitive edge in the knee cartilage repair market with no current off-the-shelf alternatives.
The patent covers a solvent-free liquid formulation of GelrinC that conforms to cartilage wounds and is cured with UV light to form a temporary elastomeric implant.
This innovation simplifies surgical procedures and improves patient experience, potentially restoring health and enhancing quality of life for thousands needing knee cartilage repair annually.
Regentis has surpassed 50% enrollment in its FDA clinical trial for a cell-free hydrogel that regenerates cartilage through a controlled, synchronous process as it resorbs.
Found this article helpful?
Share it with your network and spread the knowledge!
Regentis Biomaterials announced that the U.S. Patent and Trademark Office has issued a new patent titled 'Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof' covering a liquid, ready-to-use formulation of its lead product GelrinC.
The patent covers a liquid, ready-to-use formulation of GelrinC as well as improved production processes that eliminate the use of organic solvents.
The liquid formulation is designed to conform precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant, simplifying surgical procedures and improving patient experience.
The patent provides protection for GelrinC through 2038.
The company has surpassed 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair.
GelrinC is Regentis' lead product, a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process for knee cartilage repair.
GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is currently available.
For more information, visit https://www.regentis.co.il/ or view the full press release at https://ibn.fm/bB9os.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life, with an initial focus on orthopedic treatments.
Curated from InvestorBrandNetwork (IBN)
